PM01183

DRUG4 trials

Sponsors

PharmaMar, Massachusetts General Hospital

Conditions

ADVANCED SOLID TUMORSBreast CancerMajor Advanced Solid Tumors Other Than ColorectalMetastatic Sarcoma

Phase 1

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

CompletedNCT00877474

PharmaMarADVANCED SOLID TUMORS

Start: 2009-03-31End: 2011-06-30Updated: 2015-11-04

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

CompletedNCT01405391

PharmaMarMajor Advanced Solid Tumors Other Than Colorectal

Start: 2011-11-30End: 2016-01-31Updated: 2016-01-15

Phase 2

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

CompletedNCT01525589

PharmaMarBreast Cancer

Start: 2012-06-13End: 2018-10-31Updated: 2020-09-25

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

CompletedNCT02448537

Massachusetts General HospitalMetastatic Sarcoma

Start: 2015-08-31End: 2019-04-01Updated: 2021-03-03

Related Papers

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.

2024-02-134 citations

A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.

2019-12-3120 citations

Antitumor activity of trabectedin and lurbinectedin in germline BRCA2 carriers with metastatic breast cancer (MBC) as compared to BRCA1 carriers: Analysis of two phase II trials.

Journal of Clinical Oncology2017-05-20